AIM: We sought to evaluate nanoliposomal irinotecan as an intravenous treatment in an orthotopic brain tumor model. MATERIALS & METHODS: Nanoliposomal irinotecan was administered intravenously in the intracranial U87MG brain tumor model in mice, and irinotecan and SN-38 levels were analyzed in malignant and normal tissues. Therapy studies were performed in comparison to free irinotecan and control treatments. RESULTS: Tissue analysis demonstrated favorable properties for nanoliposomal irinotecan, including a 10.9-fold increase in tumor AUC for drug compared with free irinotecan and 35-fold selectivity for tumor versus normal tissue exposure. As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan. A total of 33% of the animals receiving nanoliposomal irinotecan showed no residual tumor by study end compared with no survivors in the other groups. CONCLUSION: Nanoliposomal irinotecan administered systemically provides significant pharmacologic advantages and may be an efficacious therapy for brain tumors.
AIM: We sought to evaluate nanoliposomal irinotecan as an intravenous treatment in an orthotopic brain tumor model. MATERIALS & METHODS: Nanoliposomal irinotecan was administered intravenously in the intracranial U87MG brain tumor model in mice, and irinotecan and SN-38 levels were analyzed in malignant and normal tissues. Therapy studies were performed in comparison to free irinotecan and control treatments. RESULTS: Tissue analysis demonstrated favorable properties for nanoliposomal irinotecan, including a 10.9-fold increase in tumor AUC for drug compared with free irinotecan and 35-fold selectivity for tumor versus normal tissue exposure. As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan. A total of 33% of the animals receiving nanoliposomal irinotecan showed no residual tumor by study end compared with no survivors in the other groups. CONCLUSION: Nanoliposomal irinotecan administered systemically provides significant pharmacologic advantages and may be an efficacious therapy for brain tumors.
Entities:
Keywords:
drug delivery; glioma; irinotecan; liposome; nanoliposome; nanoparticle
Authors: Afroz S Mohammad; Jessica I Griffith; Chris E Adkins; Neal Shah; Emily Sechrest; Emma L Dolan; Tori B Terrell-Hall; Bart S Hendriks; Helen Lee; Paul R Lockman Journal: Pharm Res Date: 2018-01-09 Impact factor: 4.200
Authors: Chris E Adkins; Mohamed I Nounou; Tanvirul Hye; Afroz S Mohammad; Tori Terrell-Hall; Neel K Mohan; Michael A Eldon; Ute Hoch; Paul R Lockman Journal: BMC Cancer Date: 2015-10-13 Impact factor: 4.430
Authors: Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio Journal: Cancers (Basel) Date: 2022-10-10 Impact factor: 6.575
Authors: Jasgit C Sachdev; Pamela Munster; Donald W Northfelt; Hyo Sook Han; Cynthia Ma; Fiona Maxwell; Tiffany Wang; Bruce Belanger; Bin Zhang; Yan Moore; Arunthathi Thiagalingam; Carey Anders Journal: Breast Cancer Res Treat Date: 2020-11-17 Impact factor: 4.872